Clinical Trials Logo

Recurrent Diffuse Large B-Cell Lymphoma clinical trials

View clinical trials related to Recurrent Diffuse Large B-Cell Lymphoma.

Filter by:

NCT ID: NCT03321643 Not yet recruiting - Clinical trials for Refractory Diffuse Large B-Cell Lymphoma

Atezolizumab, Gemcitabine, Oxaliplatin, and Rituximab in Treating Patients With Relapsed or Refractory Transformed Diffuse Large B-Cell Lymphoma

Start date: March 9, 2018
Phase: Phase 1
Study type: Interventional

This pilot phase I trial studies the side effects of atezolizumab, gemcitabine, oxaliplatin, and rituximab and to see how well they work in treating patients with transformed diffuse large B-cell lymphoma that has come back or does not respond to treatment. Monoclonal antibodies, such as atezolizumab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as gemcitabine, oxaliplatin, and rituximab, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving atezolizumab, gemcitabine, oxaliplatin, and rituximab may work better in treating patients with transformed diffuse large B-cell lymphoma.

NCT ID: NCT03277729 Recruiting - Clinical trials for Recurrent Mantle Cell Lymphoma

Immunotherapy After Chemotherapy in Treating Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Start date: January 16, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this research is to find the best dose of genetically modified T-cells, to study the safety of this treatment, and to see how well it works in treating patients with B cell non-Hodgkin lymphoma that has come back or did not respond to previous treatment.

NCT ID: NCT03272633 Not yet recruiting - Clinical trials for Myelodysplastic Syndrome

Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies

Start date: January 5, 2018
Phase: Phase 2
Study type: Interventional

This pilot clinical trial studies the side effects of irradiated donor cells following stem cell transplant in controlling cancer in patients with hematologic malignancies. Transfusion of irradiated donor cells (immune cells) from relatives may cause the patient's cancer to decrease in size and may help control cancer in patients receiving a stem cell transplant.

NCT ID: NCT03233854 Recruiting - Clinical trials for Refractory Diffuse Large B-Cell Lymphoma

CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Patients With Recurrent or Refractory CD19 Positive Diffuse Large B-Cell Lymphoma or B Acute Lymphoblastic Leukemia

Start date: September 1, 2017
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects of CD19/CD22 chimeric antigen receptor (CAR) T cells when given together with chemotherapy, and to see how well they work in treating patients with CD19 positive diffuse large B-cell lymphoma or B acute lymphoblastic leukemia that has come back or does not respond to treatment. A CAR is a genetically-engineered receptor made so that immune cells (T cells) can attack cancer cells by recognizing and responding to the CD19/CD22 proteins. These proteins are commonly found on diffuse large B-cell lymphoma and B acute lymphoblastic leukemia. Drugs used in chemotherapy, such as cyclophosphamide and fludarabine phosphate, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving CD19/CD22-CAR T cells and chemotherapy may work better in treating patients with diffuse large B-cell lymphoma or B acute lymphoblastic leukemia.

NCT ID: NCT03150329 Recruiting - Clinical trials for Recurrent Grade 1 Follicular Lymphoma

Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma

Start date: September 1, 2017
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of vorinostat when given together with pembrolizumab in treating patients with diffuse large B-cell lymphoma, follicular lymphoma, or Hodgkin lymphoma that has come back after a period of improvement or that does not respond to treatment. Monoclonal antibodies, such as pembrolizumab block cancer growth in different ways by targeting certain cells. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving vorinostat and pembrolizumab together may work better in treating patients with diffuse large B-cell lymphoma, follicular lymphoma, or Hodgkin lymphoma.

NCT ID: NCT03103971 Recruiting - Clinical trials for Recurrent Adult Acute Lymphoblastic Leukemia

huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Start date: November 3, 2017
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects of autologous anti-CD19chimeric antigen receptor (CAR)-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes (huJCAR014) in treating patients with relapsed or refractory B-cell non-Hodgkin lymphoma or acute lymphoblastic leukemia. huJCAR014 CAR-T cells are made in the laboratory by genetically modifying a patient's T cells and may specifically kill cancer cells that have a molecule CD19 on their surfaces.

NCT ID: NCT03038672 Not yet recruiting - Clinical trials for Refractory Diffuse Large B-Cell Lymphoma

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Start date: December 8, 2017
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well nivolumab with or without varlilumab works in treating patients with aggressive B-cell lymphomas that have come back or do not respond to treatment. Monoclonal antibodies, such as varlilumab and nivolumab, may work by stimulating the immune system to attack cancer tumor cells.

NCT ID: NCT03035331 Recruiting - Clinical trials for Recurrent Mantle Cell Lymphoma

Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma

Start date: March 27, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the best dose and side effects of dendritic cell therapy, cryosurgery and pembrolizumab in treating patients with non-Hodgkin lymphoma. Vaccines, such as dendritic cell therapy made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells. Cryosurgery kills cancer cells by freezing them. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving dendritic cell therapy, cryosurgery and pembrolizumab may work better at treating non-Hodgkin lymphoma.

NCT ID: NCT03015896 Suspended - Clinical trials for Recurrent Mantle Cell Lymphoma

Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Start date: February 14, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This I/II trial studies the side effects and best dose of lenalidomide when given together with nivolumab and to see how well they work in treating patients with non-Hodgkin or Hodgkin lymphoma that has come back and does not respond to treatment. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab and lenalidomide may work better in treating patients with non-Hodgkin or Hodgkin lymphoma.

NCT ID: NCT02992522 Recruiting - Clinical trials for Recurrent Marginal Zone Lymphoma

Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Start date: February 21, 2017
Phase: Phase 1
Study type: Interventional

This phase I study studies the side effects and best dose of venetoclax and lenalidomide when given together with obinutuzumab in treating patients with B-cell non-Hodgkin lymphoma that has returned after a period of improvement or not responding to treatment. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. Venetoclax may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving obinutuzumab, venetoclax, and lenalidomide may work better in treating patients with B-cell non-Hodgkin lymphoma.